We’re making significant strides in developing next-generation T cell engagers aimed at improving cancer treatment. These innovative therapies are designed to address challenges with current treatments, such as limited efficacy against solid tumors and dose-limiting toxicities. In this Drug Discovery World article, our Chief Scientific Officer, Paul Moore, PhD, and our Director of Preclinical, Multispecific Antibody Therapeutics, Nina E. Weisser, PhD, share insights into our research and its potential impact on the landscape of antibody-drug conjugates and T cell engagers. Read more here: https://lnkd.in/e55maHmb #CancerResearch #Immunotherapy #TCellEngagers #AntibodyDrugConjugates #Oncology #NextGenTherapies #PrecisionMedicine #DrugDiscovery #CancerTreatment #Biotech #CancerTherapies #ClinicalResearch
Zymeworks Inc.
Biotechnology Research
Vancouver, BC 26,511 followers
Developing novel medicines for patients with difficult-to-treat cancers and other serious diseases.
About us
Zymeworks is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. A Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for the HER2-targeted bispecific antibody zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC) has been submitted. If approved, zanidatamab would be the first HER2-targeted treatment specifically approved for BTC in the U.S. Zymeworks is rapidly advancing a deep pipeline of product candidates based on its experience and capabilities in both antibody-drug conjugates and multispecific antibody therapeutics across multiple novel targets in indications that represent areas of significant unmet medical need. In addition to Zymeworks’ wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies.
- Website
-
http://www.zymeworks.com
External link for Zymeworks Inc.
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Vancouver, BC
- Type
- Public Company
- Founded
- 2003
- Specialties
- antibody therapeutics, bispecific antibodies, effector function modulation, ADC, Breast Cancer, Gastric Cancer, protein engineering, Immune redirection, and Biliary Tract Cancer
Locations
-
Primary
540 - 1385 West 8th Ave
Vancouver, BC V6H 3V9, CA
Employees at Zymeworks Inc.
-
Daniel Dex
Senior Vice President, Corporate Secretary and General Counsel at Zymeworks Inc.
-
Michelle Seltenrich
Director, FP&A
-
Derek Miller
Life sciences executive, board member, consultant and mentor with a successful track record of 25 years across Corporate Development, Business…
-
Carlos Campoy
Board Director | Retired Public Company CFO | Audit Committee Chair | Global Business Perspective | Strategic Business Partner | Life Sciences Leader…
Updates
-
In the spirit of #PRIDE2024, Vancouver Pride Society will be hosting a variety of events to celebrate the limitless potential of Canada’s diverse and vibrant 2SLGBTQAI community as part of this year’s theme, “Infinite Horizons”. The Vancouver Pride Society will be kicking off Canada Pride 2024 today in Davie Village, featuring inspiring speakers from the local community that will set the stage for celebration. Learn how you can get involved: https://lnkd.in/esNGmvep
-
Save the date! Join us on August 1 at BrewHall in Vancouver for the inaugural Pride in Biotech event hosted by our ZYME&Proud team. ZYME&Proud is an internal employee-led committee dedicated to supporting the #LGBTQ community and allies at Zymeworks through education, advocacy, and community engagement. Through Pride in Biotech, we hope to create a nurturing environment where everyone is accepted for who they are and their diverse perspectives and experiences. We look forward to meeting members of the Vancouver #biotech and #lifesciences community next week! Register now: https://lnkd.in/eJwKZs3y
-
Our TriTCE Co-Stim platform is a next generation trispecific T cell engager platform with integrated CD28 costimulation. By providing balanced activation of both Signal 1 (CD3) and costimulatory Signal 2 (through CD28) within a single molecule, TriTCE Co-Stim molecules have the potential to induce more sustainable T cell responses in the tumor and increase therapeutic responses beyond that achievable by bispecific TCEs. #ICYMI, our Director of Preclinical, Multispecific Antibody Therapeutics, Nina E. Weisser, PhD, explains how our next generation TriTCE Co-Stim platform is engineered to address solid tumors in this Drug Target Review Q&A. See here: https://lnkd.in/ewRJvPA9
-
We are pleased to receive clearance from the FDA of our investigational new drug application for our novel folate receptor-⍺ (FR⍺) targeted topoisomerase I inhibitor antibody-drug conjugate (ADC). FR⍺ is a clinically validated target that is expressed in approximately 75% of ovarian carcinomas and 70% of non-small cell lung cancer. This is an exciting milestone for our team, showcasing the strength of our approach in developing best-in-class ADCs. For more information, see our press release: https://lnkd.in/eyXTC9VJ #OvarianCancer #LungCancer #NonSmallCellLungCancer #ADCs #AntibodyDrugConjugates #CancerResearch #Oncology #ClinicalTrials #DrugDevelopment
-
We’re searching for an Associate Director of Immunology to work with and direct our talented team of #immunology researchers to deliver an innovative and sustainable pipeline across a diversity of modalities, from inception through IND in autoimmune diseases. This individual will support the development of immunology portfolio strategy and attainment of departmental scientific and pipeline goals and through managing research, people and resources. This role is based in our Vancouver office and requires 10 years of directly relevant #biotech and #pharma industry experience in immune oncology and/or immunology. Learn more: https://lnkd.in/egvhtGva #Zymeworks #Hiring #WeAreHiring #Biotech #BiotechJobs #Opportunity #DrugDevelopment #DrugDiscovery #OpenToWork #GreatPlaceToWork #Careers #OncologyJobs #ADCtechnology #MultifunctionalTherapeutics #BiotechCareers
-
Join our CEO Kenneth Galbraith and executive leadership team on August 1 at 4:30pm ET for a conference call and webcast to discuss Q2 2024 financial results and corporate updates. See our press release: https://lnkd.in/e77jJmsZ
-
At Zymeworks, we're committed to fostering an inclusive environment where everyone has equal opportunities to grow. Learn more about our culture and check out available opportunities: https://lnkd.in/eiyDybK3 #Hiring #WeAreHiring #Biotech #BiotechJobs #Opportunity #DrugDevelopment #DrugDiscovery #OpenToWork #GreatPlaceToWork #Careers #OncologyJobs #NowHiring #ADCtechnology #MultifunctionalTherapeutics #BiotechCareers
-
Happy #IndependenceDay to our colleagues, partners, and friends in the U.S.!
-
Happy #CanadaDay to all our Canadian colleagues and friends! Today, we celebrate the vibrant culture, diversity, and beauty of Canada. Our offices will be closed this week for summer break to allow our team members to rest, relax, and enjoy quality time with their families and friends.